• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

扭转平衡:肝毒性与肝脂肪变性的4个关键事件

Tipping the Balance: Hepatotoxicity and the 4 Apical Key Events of Hepatic Steatosis.

作者信息

Angrish Michelle M, Kaiser Jonathan Phillip, McQueen Charlene A, Chorley Brian N

机构信息

*National Health and Environmental Effects Research Laboratory, Office of Research and Development (ORD), United States Environmental Protection Agency (US EPA), Research Triangle Park, North Carolina 27709;

United States Environmental Protection Agency (US EPA), National Center for Environmental Assessment, Office of Research and Development (ORD), Cincinnati, Ohio 45268.

出版信息

Toxicol Sci. 2016 Apr;150(2):261-8. doi: 10.1093/toxsci/kfw018. Epub 2016 Mar 15.

DOI:10.1093/toxsci/kfw018
PMID:26980302
Abstract

Hepatic steatosis is a condition were fat accumulates in the liver and it is associated with extra-hepatic diseases related to metabolic syndrome and systemic energy metabolism. If not reversed, steatosis can progress to steatohepatitis and irreversible stages of liver disease including fibrosis, cirrhosis, hepatocellular carcinoma, and death. From a public health standpoint, identifying chemical exposures that may be factors in steatosis etiology are important for preventing hepatotoxicity and liver disease progression. It is therefore important to identify the biological events that are key for steatosis pathology mediated by chemical exposure. In this review, we give a current overview of the complex biological cascades that can disrupt lipid homeostasis in hepatocytes in the context of 4 apical key events central to hepatic lipid retention: hepatic fatty acid (FA) uptake,de novoFA and lipid synthesis, FA oxidation, and lipid efflux. Our goal is to review these key cellular events and visually summarize them using a network for application in pathway-based toxicity testing. This effort provides a foundation to improve next-generation chemical screening efforts that may be used to prevent and ultimately reverse the growing incidence of fatty liver disease in our population.

摘要

肝脂肪变性是一种脂肪在肝脏中蓄积的病症,它与代谢综合征和全身能量代谢相关的肝外疾病有关。如果不逆转,脂肪变性可进展为脂肪性肝炎以及肝病的不可逆阶段,包括肝纤维化、肝硬化、肝细胞癌,甚至死亡。从公共卫生的角度来看,识别可能是脂肪变性病因的化学暴露因素对于预防肝毒性和肝病进展至关重要。因此,识别化学暴露介导的脂肪变性病理关键生物学事件很重要。在本综述中,我们概述了当前复杂的生物学级联反应,这些反应在肝脏脂质潴留的4个关键顶端事件(肝脂肪酸(FA)摄取、FA和脂质从头合成、FA氧化以及脂质流出)的背景下可破坏肝细胞中的脂质稳态。我们的目标是回顾这些关键细胞事件,并使用网络直观地总结它们,以便应用于基于通路的毒性测试。这项工作为改进下一代化学筛选工作奠定了基础,这些筛选工作可用于预防并最终扭转我国人群中脂肪肝疾病发病率不断上升的趋势。

相似文献

1
Tipping the Balance: Hepatotoxicity and the 4 Apical Key Events of Hepatic Steatosis.扭转平衡:肝毒性与肝脂肪变性的4个关键事件
Toxicol Sci. 2016 Apr;150(2):261-8. doi: 10.1093/toxsci/kfw018. Epub 2016 Mar 15.
2
Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in liver fatty acid binding protein null mice.肝脏脂肪酸结合蛋白缺失小鼠中肝脏微粒体甘油三酯转移蛋白缺失对肝纤维化的预防作用
Hepatology. 2017 Mar;65(3):836-852. doi: 10.1002/hep.28941. Epub 2017 Jan 19.
3
PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.过氧物酶体增殖物激活受体激动剂可减少油酸超负荷 HepaRG 细胞中的脂肪变性。
Toxicol Appl Pharmacol. 2014 Apr 1;276(1):73-81. doi: 10.1016/j.taap.2014.02.001. Epub 2014 Feb 15.
4
Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.脂肪限制和代谢因素在肥胖糖尿病小鼠脂肪变性进展为脂肪性肝炎中的作用
J Gastroenterol Hepatol. 2009 Oct;24(10):1658-68. doi: 10.1111/j.1440-1746.2009.05996.x.
5
Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.限制蛋氨酸摄入可防止瘦素缺乏型肥胖小鼠的肝脂肪变性进展。
Metabolism. 2013 Nov;62(11):1651-61. doi: 10.1016/j.metabol.2013.06.012. Epub 2013 Aug 5.
6
Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis.非酒精性脂肪性肝病:肝脂肪变性的分子机制。
Clin Mol Hepatol. 2013 Sep;19(3):210-5. doi: 10.3350/cmh.2013.19.3.210. Epub 2013 Sep 30.
7
Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.脂质代谢与肝脏炎症。二、脂肪肝疾病与脂肪酸氧化。
Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G852-8. doi: 10.1152/ajpgi.00521.2005.
8
Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis.脂质代谢与肝脏炎症。一、肝脏脂肪酸摄取:在脂肪变性中的可能作用。
Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G194-8. doi: 10.1152/ajpgi.00413.2005.
9
PFOS-induced hepatic steatosis, the mechanistic actions on β-oxidation and lipid transport.全氟辛烷磺酸诱导的肝脂肪变性,对β-氧化和脂质转运的作用机制
Biochim Biophys Acta. 2012 Jul;1820(7):1092-101. doi: 10.1016/j.bbagen.2012.03.010. Epub 2012 Mar 28.
10
Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.烟酸在非酒精性脂肪性肝病大鼠模型中预防和逆转肝脂肪变性的治疗作用。
Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G320-7. doi: 10.1152/ajpgi.00181.2013. Epub 2013 Dec 19.

引用本文的文献

1
Environmental Pollutants, Occupational Exposures, and Liver Disease.环境污染物、职业暴露与肝脏疾病
Semin Liver Dis. 2025 Jun;45(2):148-166. doi: 10.1055/a-2540-2861. Epub 2025 Mar 21.
2
Computational Strategies for Assessing Adverse Outcome Pathways: Hepatic Steatosis as a Case Study.计算策略评估不良结局途径:以肝脂肪变性为例。
Int J Mol Sci. 2024 Oct 17;25(20):11154. doi: 10.3390/ijms252011154.
3
Community-Engaged Research and the Use of Open Access ToxVal/ToxRef In Vivo Databases and New Approach Methodologies (NAM) to Address Human Health Risks From Environmental Contaminants.
社区参与式研究以及利用开放获取的 ToxVal/ToxRef 体内数据库和新方法学(NAM)来应对环境污染物对人类健康的风险。
Birth Defects Res. 2024 Sep;116(9):e2395. doi: 10.1002/bdr2.2395.
4
A Network Toxicology Approach for Mechanistic Modelling of Nanomaterial Hazard and Adverse Outcomes.一种用于纳米材料危害和不良结局的机制建模的网络毒理学方法。
Adv Sci (Weinh). 2024 Aug;11(32):e2400389. doi: 10.1002/advs.202400389. Epub 2024 Jun 25.
5
Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.药物性肝脂肪病(DIFLD):对临床、生化和组织病理学数据的综合分析,以识别机制并与当前不良结局途径保持一致。
Int J Mol Sci. 2024 May 10;25(10):5203. doi: 10.3390/ijms25105203.
6
Investigating open access new approach methods (NAM) to assess biological points of departure: A case study with 4 neurotoxic pesticides.研究用于评估生物学起始点的开放获取新方法(NAM):以4种神经毒性杀虫剂为例的案例研究
Curr Res Toxicol. 2024 Feb 15;6:100156. doi: 10.1016/j.crtox.2024.100156. eCollection 2024.
7
Integrating Concentration-Dependent Toxicity Data and Toxicokinetics To Inform Hepatotoxicity Response Pathways.整合浓度依赖性毒性数据和毒代动力学信息以阐明肝毒性反应途径。
Environ Sci Technol. 2023 Aug 22;57(33):12291-12301. doi: 10.1021/acs.est.3c02792. Epub 2023 Aug 11.
8
A Mechanistic Framework for Integrating Chemical Structure and High-Throughput Screening Results to Improve Toxicity Predictions.整合化学结构与高通量筛选结果以改进毒性预测的机制框架。
Comput Toxicol. 2018 Nov;8:1-12. doi: 10.1016/j.comtox.2018.08.003.
9
A biologically based model to quantitatively assess the role of the nuclear receptors liver X (LXR), and pregnane X (PXR) on chemically induced hepatic steatosis.建立一种基于生物学的模型,定量评估核受体肝 X(LXR)和妊娠相关 X 受体(PXR)在化学诱导性肝脂肪变性中的作用。
Toxicol Lett. 2022 Apr 15;359:46-54. doi: 10.1016/j.toxlet.2022.02.002. Epub 2022 Feb 7.
10
Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns.环境暴露作为肝脏疾病的风险调节因素:已知与未知
Acta Pharm Sin B. 2021 Dec;11(12):3768-3778. doi: 10.1016/j.apsb.2021.09.005. Epub 2021 Sep 10.